Galmed Pharmaceuticals
GLMD
21 hedge funds and large institutions have $19.5M invested in Galmed Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.01% less ownership
Funds ownership: 0.17% → 0.16% (-0.01%)
13% less funds holding
Funds holding: 24 → 21 (-3)
17% less capital invested
Capital invested by funds: $23.4M → $19.5M (-$3.95M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
California Public Employees Retirement System
Sacramento,
California
|
+$296K |
| 2 |
Renaissance Technologies
New York
|
+$283K |
| 3 |
Morgan Stanley
New York
|
+$112K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$35.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$506K |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$480K |
| 3 |
VC
Voss Capital
Houston,
Texas
|
-$443K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$306K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$254K |
GLMD Hedge Fund Activity: Q4 2020 in Review
21 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2020, worth a combined $19.5M — down 17% from $23.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GLMD and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was California Public Employees Retirement System, opening a new position worth an estimated $296K. The largest seller was Nantahala Capital Management, cutting an estimated $506K.
- 21 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2020, down from 24 in Q3 2020.
- Funds reported $19.5M of Galmed Pharmaceuticals stock for Q4 2020, down 17% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q4 2020 and 7 closed out, a net change of -3 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2020 was California Public Employees Retirement System, an estimated $296K added.
- The largest Galmed Pharmaceuticals seller in Q4 2020 was Nantahala Capital Management, an estimated $506K sold.
Based on aggregated 13F filings for Q4 2020.